Dallas, U.S. | January 20, 2026
Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas, marking a strategic expansion of the program beyond hematologic malignancies into solid tumors with high unmet need.
This is the third orphan designation for LP-284 and the sixth overall across Lantern’s AI-enabled oncology portfolio, reinforcing the company’s regulatory momentum as it advances biomarker-driven cancer therapies.
Strategic Expansion into Adult Soft Tissue Sarcomas
Soft tissue sarcomas represent a clinically challenging and commercially underserved oncology segment, with approximately 96,000 new cases diagnosed globally each year. Unlike pediatric sarcomas—often driven by defined gene fusions—adult soft tissue sarcomas typically exhibit complex genomic instability and DNA repair deficiencies, creating a strong biological rationale for LP-284’s mechanism of action.
More than 79% of cases occur in adults, and outcomes for advanced or metastatic disease remain poor, with five-year survival rates below 20%, underscoring a significant therapeutic gap.
The global market for soft tissue sarcoma therapies across major pharmaceutical regions was valued at ~$2.4 billion in 2025 and is projected to reach ~$4.7 billion by 2035, positioning LP-284 as a potentially differentiated entrant in a growing rare oncology market.
AI-Identified Synthetic Lethality Targets DNA Repair Vulnerabilities
LP-284 is a novel small-molecule therapy designed to exploit DNA repair defects through a synthetic lethal mechanism, specifically targeting transcription-coupled nucleotide excision repair (TC-NER) pathways. The drug was identified and optimized using Lantern’s proprietary RADR® AI platform, which integrates large-scale genomic, pharmacologic, and clinical datasets to predict therapeutic response.
Importantly, LP-284 has demonstrated activity independent of TP53 mutation status or surface antigen expression, broadening its applicability across genetically heterogeneous tumors.
Clinical Signal Supports Broader Oncology Potential
In mid-2025, LP-284 achieved a complete metabolic response in a heavily pretreated patient with aggressive diffuse large B-cell lymphoma during an ongoing Phase I trial—despite prior failure of chemotherapy, CAR-T therapy, and bispecific antibodies. This result provided early clinical validation of LP-284’s synthetic lethal approach in treatment-refractory disease.
Lantern believes the same DNA repair vulnerabilities observed in resistant hematologic cancers are prevalent in adult soft tissue sarcomas, supporting the program’s expansion into solid tumors.
Regulatory Advantages Accelerate Development Pathway
The FDA’s Orphan Drug Designation provides LP-284 with multiple development and commercialization advantages, including:
- Seven years of U.S. market exclusivity upon approval
- Tax credits for qualified clinical trials
- Exemption from FDA user fees
- Regulatory guidance to support efficient trial design
LP-284 is currently being evaluated in a Phase I clinical trial for B-cell non-Hodgkin lymphomas, with future studies expected to explore additional solid tumor indications guided by AI-identified biomarkers.
AI as a Catalyst for Rare Cancer Innovation
With LP-284 now holding orphan designations across both hematologic and solid tumors, Lantern Pharma continues to position its AI-first drug development model as a catalyst for unlocking precision therapies in rare and genomically complex cancers where conventional approaches have fallen short.
BioNext Market Insights – Strategic Takeaway:
Lantern’s latest orphan designation highlights how AI-guided synthetic lethality strategies are reshaping rare oncology development—reducing risk, accelerating regulatory pathways, and expanding market optionality across traditionally hard-to-treat cancers.
By
